Graphite Bio, Inc launches an IPO

IPO of GRAPHITE BIO, INC. will take place on June, 24 2021.

Graphite Bio is a biotech next-generation gene-editing company. The company uses the high-performance targeted gene integration to develop a new cure method able to treat and cure a wide range of grave and life-threatening diseases. GRAPHITE BIO are pioneers in gene-editing focused on a goal to precisely replace a damaged portion of a gene or insert new genetic information to treat disease. Their highly differentiated gene integration platform harnesses the power of CRISPR and natural DNA repair processes to achieve targeted gene integration to repair genetic defects at their source, to replace genes causing diseases by intact genes or to insert new genes into defined safe places.  

The listed IPO bookrunners are Morgan Stanley, BofA Securities, Cowen и SVB Leerink.